Objective Patients with cystic fibrosis (CF) and mutations associated with residual CFTR chloride transport have improved survival rates compared with those homozygous for the F508del-CFTR mutation. Since little is known about rate of lung function decline in patients with CF and residual function (RF) mutations, we evaluated differences in rates of percent predicted FEV 1 (ppFEV 1 ) decline between patients with an RF mutation who were heterozygous for F508del and those who were homozygous for F508del, and whether rates of ppFEV 1 decline differed across age groups. Methods Patients in the US CF Foundation Patient Registry from 2006 to 2014 with an RF mutation heterozygous for F508del were compared with F508del-homozygous patients. Mutations were identified based on clinical or in vitro evidence of residual ion transport. Annual rates of ppFEV 1 decline were estimated for patients 6 to 45 years of age with !3 ppFEV 1 values spanning !0.5 years in a randomly chosen 2 year period that began at the first ppFEV 1 measurement in the calendar year. Results A total of 1242 RF and 11,916 F508del-homozygous patients were included. At the first visit, the RF cohort was older (mean [SD] Introduction Lung cancer is the leading cause of cancer death worldwide with over 70% presenting with incurable disease and few effective treatments. We previously demonstrated that mesenchymal stem cells (MSCs) transduced to express TNFrelated apoptosis inducing ligand (TRAIL), will home to and induce apoptosis of tumour cells in vitro and reduce tumour growth in multiple in vivo models. We are now undertaking a clinical trial to assess the therapeutic efficacy of this genetically modified cell therapy. Aim To evaluate the safety and anti-tumour activity of MSCTRAIL in combination with chemotherapy in patients with metastatic lung adenocarcinoma. Manufacturing Methods MSCs were isolated from unrelated umbilical cord donors and characterised as MSCs according to international criteria. Cells from individual donors were thawed and transduced with a lentiviral vector encoding for Abstract P256 Figure 1A Phase I Schema.
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